Analysis of:
UCB's Vimpat(R) approved by U.S. FDA as adjunctive therapy for partial onset seizures in adults (www.pipelinereview.com)
FDA has approved lacosamide for add-on therapy of partial onset seizures. It will be marketed by UCB under the brand name Vimpat.
Analysis of:
New data show Tekturna HCT® is twice as effective at reducing blood pressure than the diuretic HCT alone (www.novartis.com)
Tecturna or Aliskerin belongs to the new anti hypertensive medication class of direct renin inhibitor. The basic action is to inhibit the renin angiotensin/aldosterone system. As we all have understanding of how ace-i and ARB act in this system at different points and effect the blood pressure,...
Analysis of:
Artificial Disc Versus Fusion: A Prospective, Randomized Study With 2-Year Follow-up on 99 Patients (www.medscape.com)
Outcomes in patients implanted with the artificial disc compare favorably with single level ACDF after 2 years.
Analysis of:
UCB Announces FDA Filing for lacosamide in the Treatment of Partial Onset Seizures (www.reuters.com)
UCB has filed new drug application for regulatory approval for lacosamide through FDA and European Medicines Agency. Primary indication would be the treatment of partial onset seizures (epilepsy)
Analysis of:
Shire announces results of Fosrenol(R) study in pre-dialysis CKD stage 3 & 4 patients (www.pipelinereview.com)
1. Non- calcium containing binders 2. Good phosphate control 3. Need to keep watching as much longer safety data would help
Analysis of:
Prometic Reports Positive Pre-Clinical Data for PBI-1402 in Anemia Related to Renal Failure (www.marketwire.com)
1. Oral erythropoiesis stimulating product may positively impact compliance in non- dialysis ckd patients 2. It would be important to see the potency of the medication. 3. Are there any drug interactions or concerning side effects
Analysis of:
Painkiller Widely Abused in South (www.washingtonpost.com)
The article describes the increase in hydrocodone abuse, especially in the Southern and Rural US.
Analysis of:
American's Gamble for Bargain Surgery Abroad (www.medpagetoday.com)
The article describes several examples of medical tourism with different motivations and risks involved.
Analysis of:
Oncoscience AG, the european partner of YM BioSciences, announces completion of patient enrollment in phase III brain cancer trial of nimotuzab (www.pipelinereview.com)
The articel discusses Oncoscience AG, the european partner of YM BioSciences experimenal treatment for gliomas. It is based on a monoclonal antibody to EGFR and is being tested in combination with other treatments including radiation.
Analysis of:
New Treatment Boosts Muscle Function In Myasthenia Gravis (www.medicalnewstoday.com)
The article reports on an open label study recently published in Neurology. Apparently a new treatment (oral EN101 antisense) appears to be effective at improving muscle strength and reducing fatigue in people with MG.